EExelixis Inc. NASDAQ: EXEL) on Monday reported final overall survival data from the Phase 3 STELLAR-303 trial.
The data showed that the investigational combination of zanzalintinib and atezolizumab demonstrated a numerical overall survival benefit, but failed to achieve statistical significance in a subgroup of metastatic colorectal cancer patients without active liver metastases.
Zanzalintinib (formerly known as XL092) is an investigational, third-generation oral tyrosine kinase inhibitor (TKI) designed as a next-generation successor to Exelixis flagship cancer medicine, cabozantinib.
Final Analysis Shows Numerical Survival Advantage
The final analysis of one of the trial’s dual primary endpoints evaluated overall survival in patients with previously treated non-microsatellite instability-high metastatic colorectal cancer (mCRC) who did not have active liver metastases at baseline.
